Close
Nordic 9Nordic 9

Acorn Bioventures (investor - Venture Capital)

United States acornbioventures.com
See something wrong or missing? Let us know
Offices:New York

Acorn Bioventures invests across stages in small-cap public and private biotechnology companies focused on bringing novel innovative medicines to patients

Average round investment:35.5M USD
Average number per year:1.0
Distribution: 2024 (1)2020 (1)
Portfolio companies: Switzerland NeurosterixIreland ONK Therapeutics
Mostly invests in: Switzerland Switzerland (1) Biotech (2)

2 tracked investments in:

You need an account to access this feature. Log in or create one from here.

Do you have a question? Talk to us.

Investors with similar profile to Acorn Bioventures

Name Criteria
Sweden Recipharm Venture Fund
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services, Pharma, Manufacturing
  • Similar business models: B2B
  • Common investees countries: Switzerland
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
United Kingdom Rosetta Capital
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services, Pharma
  • Similar business models: B2B
  • Common investees countries: Ireland
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
Germany Fresenius Medical Care Ventures
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services, Manufacturing
  • Similar business models: B2B
  • Common investees countries: Switzerland
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
Switzerland GF Group
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services, Manufacturing
  • Similar business models: B2B
  • Common investees countries: Switzerland
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
United States Walden Catalyst Ventures
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services, Manufacturing
  • Similar business models: B2B
  • Common investees countries: Switzerland
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
United States YA II PN
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Pharma, Manufacturing
  • Similar business models: B2B
  • Common investees countries: Switzerland
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
United States 10X Capital
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services, Pharma
  • Similar business models: B2B
  • Common investees countries: Switzerland
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
France Pierre Fabre Invest
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services, Manufacturing
  • Similar business models: B2B
  • Common investees countries: Switzerland
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
United States Revelation Partners
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services, Pharma
  • Similar business models: B2B
  • Common investees countries: Switzerland
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
United States Cleveland Avenue
83%
  • Range for average deal size: 20M - 50M USD
  • Similar verticals: Biotech, Health services, Manufacturing
  • Similar business models: B2B
  • Common investees countries: Ireland
  • Average number of deals per year: 1.3
  • Active last 12 months: Yes
Top